Long-Term Testosterone Administration on Insulin Sensitivity in Older Men With Low or Low-Normal Testosterone Levels
Abstract Background Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-nor...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 103; no. 4; pp. 1678 - 1685 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
Endocrine Society
01.04.2018
Copyright Oxford University Press Oxford University Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-972X 1945-7197 1945-7197 |
| DOI | 10.1210/jc.2017-02545 |
Cover
| Abstract | Abstract
Background
Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown.
Methods
The Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry.
Results
There was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects.
Conclusion
Testosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity.
Testosterone levels and insulin sensitivity both decrease with age. We found that long-term testosterone therapy for 36 months in nondiabetic older men did not improve insulin sensitivity. |
|---|---|
| AbstractList | Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown.BackgroundSerum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown.The Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry.MethodsThe Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry.There was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects.ResultsThere was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects.Testosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity.ConclusionTestosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity. Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown. The Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry. There was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects. Testosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity. Abstract Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown. The Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry. There was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects. Testosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity. Testosterone levels and insulin sensitivity both decrease with age. We found that long-term testosterone therapy for 36 months in nondiabetic older men did not improve insulin sensitivity. Background Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown. Methods The Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry. Results There was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects. Conclusion Testosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity. Testosterone levels and insulin sensitivity both decrease with age. We found that long-term testosterone therapy for 36 months in nondiabetic older men did not improve insulin sensitivity. Abstract Background Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin resistance. However, the effects of long-term testosterone administration on insulin sensitivity in older men with low or low-normal testosterone levels remain unknown. Methods The Testosterone Effects on Atherosclerosis in Aging Men Trial was a placebo-controlled, randomized, double-blind trial. The participants were 308 community-dwelling men, ≥60 years old, with total testosterone 100 to 400 ng/dL or free testosterone <50 pg/mL. A subset of 134 nondiabetic men (mean age, 66.7 ± 5.1 years) underwent an octreotide insulin suppression test at baseline and at 3 and 36 months after randomization to measure insulin sensitivity. Insulin sensitivity was estimated as the steady-state plasma glucose (SSPG) concentration at equilibrium during octreotide and insulin administration. Secondary outcomes included total lean mass (TLM) and total fat mass (TFM) by dual energy x-ray absorptiometry. Results There was a significant (P = 0.003) increase in SSPG in the placebo group, whereas no change was seen in testosterone-treated subjects from baseline to 36 months; however, the between-group differences in change in SSPG over 3 years were not statistically significant (+15.3 ± 6.9 mg/dL in the placebo group vs +6.2 ± 6.4 mg/dL in the testosterone group; mixed-model effect, P = 0.17). Changes in SSPG with testosterone treatment were not associated with changes in serum total or free testosterone concentrations. Changes in TFM but not TLM were associated with increases in SSPG. Stratification by age or baseline total testosterone level did not show significant intervention effects. Conclusion Testosterone administration for 36 months in older men with low or low-normal testosterone levels did not improve insulin sensitivity. Testosterone levels and insulin sensitivity both decrease with age. We found that long-term testosterone therapy for 36 months in nondiabetic older men did not improve insulin sensitivity. |
| Author | Pencina, Karol M Bhasin, Shalender Travison, Thomas G Li, Zhuoying Storer, Thomas W Tsitouras, Panayiotis Huang, Grace Basaria, Shehzad Harman, S Mitchell |
| AuthorAffiliation | Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts Kronos Longevity Research Institute, Phoenix, Arizona Phoenix VA Health Care System, Phoenix, Arizona Department of Geriatric Medicine, University of Oklahoma HSC, Oklahoma City, Oklahoma |
| AuthorAffiliation_xml | – name: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts Kronos Longevity Research Institute, Phoenix, Arizona Phoenix VA Health Care System, Phoenix, Arizona Department of Geriatric Medicine, University of Oklahoma HSC, Oklahoma City, Oklahoma – name: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, MA Institute for Aging Research, Hebrew Senior Life, Boston, Massachusetts Kronos Longevity Research Institute, Phoenix, Arizona Phoenix VA Health Care System, Phoenix, Arizona Department of Geriatric Medicine, University of Oklahoma HSC, Oklahoma City, OK – name: 5 Department of Geriatric Medicine, University of Oklahoma HSC, Oklahoma City, Oklahoma – name: 2 Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts – name: 3 Kronos Longevity Research Institute, Phoenix, Arizona – name: 4 Phoenix VA Health Care System, Phoenix, Arizona – name: 1 Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts |
| Author_xml | – sequence: 1 givenname: Grace surname: Huang fullname: Huang, Grace email: ghuang7@partners.org organization: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts – sequence: 2 givenname: Karol M surname: Pencina fullname: Pencina, Karol M organization: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts – sequence: 3 givenname: Zhuoying surname: Li fullname: Li, Zhuoying organization: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts – sequence: 4 givenname: Shehzad surname: Basaria fullname: Basaria, Shehzad organization: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts – sequence: 5 givenname: Shalender surname: Bhasin fullname: Bhasin, Shalender organization: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts – sequence: 6 givenname: Thomas G surname: Travison fullname: Travison, Thomas G organization: Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts – sequence: 7 givenname: Thomas W surname: Storer fullname: Storer, Thomas W organization: Section of Men’s Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women’s Hospital-Harvard Medical School, Boston, Massachusetts – sequence: 8 givenname: S Mitchell surname: Harman fullname: Harman, S Mitchell organization: Kronos Longevity Research Institute, Phoenix, Arizona – sequence: 9 givenname: Panayiotis surname: Tsitouras fullname: Tsitouras, Panayiotis organization: Kronos Longevity Research Institute, Phoenix, Arizona |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29373734$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1vEzEQtVARTQtHrmglLlxc_O3sBamqgFYK9EAQ3KzN7mzj4LVTezdR_32dJgEaqZVtWSO_9zxvZk7QkQ8eEHpLyRlllHxc1GeMUI0Jk0K-QCNaCok1LfURGhHCKC41-32MTlJaEEKFkPwVOmYl13mJEeonwd_gKcSumELqQ-oh5g-K86az3qY-Vr0Nvsj7yqfBWV_8AJ9sb1e2vytyeO0aiMU38MUv28-LSVgXIW4u_D3ErnKPZSewApdeo5dt5RK82d2n6OeXz9OLSzy5_np1cT7BtWTZBcy4bktRVrLhmkhFpa6ZaqVoOcgGZM3bcctnQoEgqhTQ1IoBVVw0rGqasuan6NNWdznMuvwMPvtxZhltV8U7EyprHr94Ozc3YWUU00oTmgU-7ARiuB2yEdPZVINzlYcwJEPLkhEyZmycoe8PoIswRJ_tGU412aA4ew7FCCcqCymRUe_-z_tvwvu2ZQDfAuoYUorQmtr2D53KNqwzlJjNcJhFbTbDYR6GI7PwAWsv_BSebvHr4HL_0h83rCGaOVSunx9y8J4jnuHkMhCh9BhnxpiIHOF8JPtX6DAsn8pq98M9SsXm_A |
| CitedBy_id | crossref_primary_10_1210_er_2018_00178 crossref_primary_10_1155_2021_8799537 crossref_primary_10_1038_s41569_019_0211_4 crossref_primary_10_1111_dme_13977 crossref_primary_10_1111_nyas_15211 crossref_primary_10_3389_fendo_2019_00372 crossref_primary_10_1097_MED_0000000000000884 crossref_primary_10_1016_j_ecl_2021_11_006 crossref_primary_10_2337_db21_1056 crossref_primary_10_3389_fmed_2018_00190 crossref_primary_10_1210_jc_2018_02015 crossref_primary_10_3390_ijms23073535 crossref_primary_10_1016_j_ecl_2022_12_002 crossref_primary_10_1038_s43856_022_00226_0 crossref_primary_10_2337_dc17_2510 crossref_primary_10_1111_dom_14206 crossref_primary_10_3390_medicina60081241 crossref_primary_10_3389_fendo_2019_00345 crossref_primary_10_1111_nyas_15188 crossref_primary_10_1016_j_biopha_2020_110423 crossref_primary_10_1016_j_esxm_2021_100403 crossref_primary_10_1111_cen_13723 crossref_primary_10_1016_j_ahj_2021_11_016 crossref_primary_10_1111_cen_13862 crossref_primary_10_1002_ajhb_23942 crossref_primary_10_1210_jc_2018_00265 crossref_primary_10_1210_jc_2018_01598 crossref_primary_10_1038_s41591_020_0751_5 |
| Cites_doi | 10.1111/j.1365-2265.2010.03845.x 10.1111/jsm.12404 10.1016/j.steroids.2009.01.008 10.1093/gerona/glq002 10.1055/s-2007-1000808 10.1002/hep.22252 10.1152/ajpendo.00678.2007 10.1530/JOE-13-0393 10.1016/0026-0495(78)90091-4 10.1172/JCI110908 10.1530/eje.1.02166 10.1210/jc.2004-1158 10.1093/gerona/glr100 10.1016/j.metabol.2012.10.002 10.1210/jc.2007-1291 10.1111/jsm.12114 10.1016/j.cca.2008.09.011 10.1007/s11010-011-0737-1 10.1093/gerona/gls259 10.1016/j.metabol.2009.05.010 10.2164/jandrol.108.005454 10.1210/jc.2016-1778 10.2337/dc11-0888 10.1210/jcem.86.2.7219 10.1093/gerona/58.12.M1103 10.2337/dc15-1518 10.1210/jc.2014-2464 10.2337/dc10-1233 10.1111/dom.12701 10.1001/jama.2015.8881 10.1038/nrendo.2013.73 10.1111/andr.12454 10.1210/jc.2004-2190 10.1093/oxfordjournals.aje.a008832 10.2337/dc13-2845 10.1111/j.1748-1716.1992.tb09452.x |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 Endocrine Society 2018 Copyright © Oxford University Press 2015 Copyright © 2018 Endocrine Society Copyright © 2018 Endocrine Society. |
| Copyright_xml | – notice: Copyright © 2018 Endocrine Society 2018 – notice: Copyright © Oxford University Press 2015 – notice: Copyright © 2018 Endocrine Society – notice: Copyright © 2018 Endocrine Society. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TM 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1210/jc.2017-02545 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | 1685 |
| ExternalDocumentID | PMC6276701 29373734 10_1210_jc_2017_02545 10.1210/jc.2017-02545 00004678-201804000-00052 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K08 HL132122 – fundername: NIA NIH HHS grantid: P30 AG031679 – fundername: NCRR NIH HHS grantid: UL1 RR025771 |
| GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 3V. 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABSAR ABWST ABXVV ACFRR ACGFO ACGFS ACPRK ACUTJ ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFZL AFGWE AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGQXC AGUTN AHMBA AI. AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVNTJ AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK G8K GAUVT GJXCC GX1 H13 HVGLF HZ~ H~9 IAO IHR INH J5H KBUDW KOP KQ8 KSI KSN L7B M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PQQKQ PROAC REU ROX ROZ TEORI TJX TLC TMA TR2 TWZ VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 7X7 88E 8FI 8FJ ABDFA ABDPE ABEJV ABGNP ABUWG ABVGC ABXZS ACVCV ADMTO ADNBA AEMQT AEOTA AFFQV AFKRA AGORE AHGBF AHMMS AJBYB AJDVS ALXQX CCPQU FYUFA HMCUK ITC M1P NU- OBFPC PHGZM PHGZT PSQYO UKHRP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM 7XB 8FK AEHZK H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS PUEGO 7X8 5PM |
| ID | FETCH-LOGICAL-c5245-eb37f949a5d37056157c26f54f3e5de5c3f8f3b46e40694edc62e1634d2add9c3 |
| IEDL.DBID | 7X7 |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Thu Aug 21 18:13:08 EDT 2025 Sun Sep 28 08:38:14 EDT 2025 Fri Sep 19 20:53:47 EDT 2025 Fri Sep 19 20:52:20 EDT 2025 Thu Apr 03 07:01:47 EDT 2025 Tue Jul 01 01:10:48 EDT 2025 Thu Apr 24 22:57:32 EDT 2025 Fri May 16 03:50:28 EDT 2025 Fri May 16 03:42:26 EDT 2025 Wed Aug 28 03:20:50 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5245-eb37f949a5d37056157c26f54f3e5de5c3f8f3b46e40694edc62e1634d2add9c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 29373734 |
| PQID | 2030628364 |
| PQPubID | 2046206 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6276701 proquest_miscellaneous_1992008228 proquest_journals_3170008232 proquest_journals_2030628364 pubmed_primary_29373734 crossref_citationtrail_10_1210_jc_2017_02545 crossref_primary_10_1210_jc_2017_02545 wolterskluwer_health_10_1210_jc_2017-02545 wolterskluwer_health_00004678-201804000-00052 oup_primary_10_1210_jc_2017-02545 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-April |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 04 year: 2018 text: 2018-April |
| PublicationDecade | 2010 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2018 |
| Publisher | Endocrine Society Copyright Oxford University Press Oxford University Press |
| Publisher_xml | – name: Endocrine Society – name: Copyright Oxford University Press – name: Oxford University Press |
| References | Muniyappa ( key 20180406135424_B30) 2000 Mimura ( key 20180406135424_B31) 1994; 26 Kapoor ( key 20180406135424_B24) 2006; 154 Huang ( key 20180406135424_B29) 2013; 68 Kalinchenko ( key 20180406135424_B28) 2010; 73 Parthasarathy ( key 20180406135424_B17) 2009; 399 Hackett ( key 20180406135424_B25) 2014; 11 Knowles ( key 20180406135424_B33) 2013; 62 Magnussen ( key 20180406135424_B27) 2016; 18 Holmboe ( key 20180406135424_B11) 2016; 101 Fink ( key 20180406135424_B1) 1983; 71 Haffner ( key 20180406135424_B6) 1996; 143 Bhasin ( key 20180406135424_B10) 2011; 34 Storer ( key 20180406135424_B14) 2017; 102 Jones ( key 20180406135424_B23) 2011; 34 Muller ( key 20180406135424_B7) 2005; 90 Muthusamy ( key 20180406135424_B18) 2009; 58 Basaria ( key 20180406135424_B39) 2008; 29 Dhindsa ( key 20180406135424_B22) 2016; 39 Pitteloud ( key 20180406135424_B36) 2005; 90 Spitzer ( key 20180406135424_B4) 2013; 9 Harano ( key 20180406135424_B32) 1978; 27 Grossmann ( key 20180406135424_B2) 2014; 220 Lin ( key 20180406135424_B21) 2008; 47 Gianatti ( key 20180406135424_B26) 2014; 37 Basaria ( key 20180406135424_B34) 2015; 314 Mazer ( key 20180406135424_B35) 2009; 74 Hsu ( key 20180406135424_B8) 2014; 99 Muthusamy ( key 20180406135424_B20) 2011; 352 Schoenfeld ( key 20180406135424_B37) 2013; 10 Harman ( key 20180406135424_B3) 2001; 86 Allan ( key 20180406135424_B15) 2008; 93 Sato ( key 20180406135424_B19) 2008; 294 Holmäng ( key 20180406135424_B38) 1992; 146 Lakshman ( key 20180406135424_B9) 2010; 65A Vermeulen ( key 20180406135424_B5) 1999; 22 Tapper ( key 20180406135424_B16) 2018; 6 Travison ( key 20180406135424_B13) 2011; 66A Bhasin ( key 20180406135424_B12) 2003; 58 30299458 - J Clin Endocrinol Metab. 2019 Mar 1;104(3):680-681 29546341 - J Clin Endocrinol Metab. 2018 May 1;103(5):2069-2070 30299455 - J Clin Endocrinol Metab. 2019 Mar 1;104(3):678-679 |
| References_xml | – volume: 73 start-page: 602 issue: 5 year: 2010 ident: key 20180406135424_B28 article-title: Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2010.03845.x – volume: 11 start-page: 840 issue: 3 year: 2014 ident: key 20180406135424_B25 article-title: Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study publication-title: J Sex Med doi: 10.1111/jsm.12404 – volume: 74 start-page: 512 issue: 6 year: 2009 ident: key 20180406135424_B35 article-title: A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations publication-title: Steroids doi: 10.1016/j.steroids.2009.01.008 – volume: 65A start-page: 503 issue: 5 year: 2010 ident: key 20180406135424_B9 article-title: Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/glq002 – volume-title: Endotext year: 2000 ident: key 20180406135424_B30 – volume: 26 start-page: 184 issue: 4 year: 1994 ident: key 20180406135424_B31 article-title: Insulin sensitivity test using a somatostatin analogue, octreotide (Sandostatin) publication-title: Horm Metab Res doi: 10.1055/s-2007-1000808 – volume: 102 start-page: 583 issue: 2 year: 2017 ident: key 20180406135424_B14 article-title: Effects of testosterone supplementation for 3 years on muscle performance and physical function in older men publication-title: J Clin Endocrinol Metab – volume: 47 start-page: 1924 issue: 6 year: 2008 ident: key 20180406135424_B21 article-title: Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor publication-title: Hepatology doi: 10.1002/hep.22252 – volume: 294 start-page: E961 issue: 5 year: 2008 ident: key 20180406135424_B19 article-title: Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00678.2007 – volume: 220 start-page: R37 issue: 3 year: 2014 ident: key 20180406135424_B2 article-title: Testosterone and glucose metabolism in men: current concepts and controversies publication-title: J Endocrinol doi: 10.1530/JOE-13-0393 – volume: 27 start-page: 1449 issue: 9 year: 1978 ident: key 20180406135424_B32 article-title: Glucose, insulin, and somatostatin infusion for the determination of insulin sensitivity in vivo publication-title: Metabolism doi: 10.1016/0026-0495(78)90091-4 – volume: 71 start-page: 1523 issue: 6 year: 1983 ident: key 20180406135424_B1 article-title: Mechanisms of insulin resistance in aging publication-title: J Clin Invest doi: 10.1172/JCI110908 – volume: 154 start-page: 899 issue: 6 year: 2006 ident: key 20180406135424_B24 article-title: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes publication-title: Eur J Endocrinol doi: 10.1530/eje.1.02166 – volume: 90 start-page: 2618 issue: 5 year: 2005 ident: key 20180406135424_B7 article-title: Endogenous sex hormones and metabolic syndrome in aging men publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2004-1158 – volume: 66A start-page: 1090 issue: 10 year: 2011 ident: key 20180406135424_B13 article-title: Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/glr100 – volume: 62 start-page: 548 issue: 4 year: 2013 ident: key 20180406135424_B33 article-title: Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp publication-title: Metabolism doi: 10.1016/j.metabol.2012.10.002 – volume: 93 start-page: 139 issue: 1 year: 2008 ident: key 20180406135424_B15 article-title: Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2007-1291 – volume: 10 start-page: 1401 issue: 5 year: 2013 ident: key 20180406135424_B37 article-title: Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis publication-title: J Sex Med doi: 10.1111/jsm.12114 – volume: 399 start-page: 49 issue: 1-2 year: 2009 ident: key 20180406135424_B17 article-title: Sex steroids enhance insulin receptors and glucose oxidation in Chang liver cells publication-title: Clin Chim Acta doi: 10.1016/j.cca.2008.09.011 – volume: 352 start-page: 35 issue: 1-2 year: 2011 ident: key 20180406135424_B20 article-title: Sex steroids influence glucose oxidation through modulation of insulin receptor expression and IRS-1 serine phosphorylation in target tissues of adult male rat publication-title: Mol Cell Biochem doi: 10.1007/s11010-011-0737-1 – volume: 68 start-page: 954 issue: 8 year: 2013 ident: key 20180406135424_B29 article-title: Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/gls259 – volume: 58 start-page: 1581 issue: 11 year: 2009 ident: key 20180406135424_B18 article-title: Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat publication-title: Metabolism doi: 10.1016/j.metabol.2009.05.010 – volume: 29 start-page: 534 issue: 5 year: 2008 ident: key 20180406135424_B39 article-title: Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth publication-title: J Androl doi: 10.2164/jandrol.108.005454 – volume: 101 start-page: 3180 issue: 8 year: 2016 ident: key 20180406135424_B11 article-title: Low testosterone: a risk marker rather than a risk factor for type 2 diabetes publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-1778 – volume: 34 start-page: 2464 issue: 11 year: 2011 ident: key 20180406135424_B10 article-title: Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the Framingham heart study publication-title: Diabetes Care doi: 10.2337/dc11-0888 – volume: 86 start-page: 724 issue: 2 year: 2001 ident: key 20180406135424_B3 article-title: Longitudinal effects of aging on serum total and free testosterone levels in healthy men publication-title: J Clin Endocrinol Metab doi: 10.1210/jcem.86.2.7219 – volume: 58 start-page: M1103 issue: 12 year: 2003 ident: key 20180406135424_B12 article-title: The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action publication-title: J Gerontol A Biol Sci Med Sci doi: 10.1093/gerona/58.12.M1103 – volume: 39 start-page: 82 issue: 1 year: 2016 ident: key 20180406135424_B22 article-title: Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc15-1518 – volume: 99 start-page: E2686 issue: 12 year: 2014 ident: key 20180406135424_B8 article-title: Associations between circulating reproductive hormones and SHBG and prevalent and incident metabolic syndrome in community-dwelling older men: the Concord Health and Ageing in Men Project publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2014-2464 – volume: 34 start-page: 828 issue: 4 year: 2011 ident: key 20180406135424_B23 article-title: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study) publication-title: Diabetes Care doi: 10.2337/dc10-1233 – volume: 18 start-page: 980 issue: 10 year: 2016 ident: key 20180406135424_B27 article-title: Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy publication-title: Diabetes Obes Metab doi: 10.1111/dom.12701 – volume: 314 start-page: 570 issue: 6 year: 2015 ident: key 20180406135424_B34 article-title: Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2015.8881 – volume: 9 start-page: 414 issue: 7 year: 2013 ident: key 20180406135424_B4 article-title: Risks and benefits of testosterone therapy in older men publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2013.73 – volume: 6 start-page: 64 issue: 1 year: 2018 ident: key 20180406135424_B16 article-title: Muscles of the trunk and pelvis are responsive to testosterone administration: data from testosterone dose-response study in young healthy men publication-title: Andrology doi: 10.1111/andr.12454 – volume: 90 start-page: 2636 issue: 5 year: 2005 ident: key 20180406135424_B36 article-title: Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2004-2190 – volume: 22 start-page: 110 issue: 5 year: 1999 ident: key 20180406135424_B5 article-title: Testosterone, body composition and aging publication-title: J Endocrinol Invest – volume: 143 start-page: 889 issue: 9 year: 1996 ident: key 20180406135424_B6 article-title: Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a008832 – volume: 37 start-page: 2098 issue: 8 year: 2014 ident: key 20180406135424_B26 article-title: Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial publication-title: Diabetes Care doi: 10.2337/dc13-2845 – volume: 146 start-page: 505 issue: 4 year: 1992 ident: key 20180406135424_B38 article-title: The effects of testosterone on insulin sensitivity in male rats publication-title: Acta Physiol Scand doi: 10.1111/j.1748-1716.1992.tb09452.x – reference: 29546341 - J Clin Endocrinol Metab. 2018 May 1;103(5):2069-2070 – reference: 30299455 - J Clin Endocrinol Metab. 2019 Mar 1;104(3):678-679 – reference: 30299458 - J Clin Endocrinol Metab. 2019 Mar 1;104(3):680-681 |
| SSID | ssj0014453 |
| Score | 2.430574 |
| Snippet | Abstract
Background
Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development... Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin... Abstract Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of insulin... Background Serum testosterone levels and insulin sensitivity both decrease with age. Severe testosterone deficiency is associated with the development of... Testosterone levels and insulin sensitivity both decrease with age. We found that long-term testosterone therapy for 36 months in nondiabetic older men did not... |
| SourceID | pubmedcentral proquest pubmed crossref wolterskluwer oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1678 |
| SubjectTerms | Age Aged Aging Arteriosclerosis Blood Glucose - analysis Body Composition - drug effects Body fat Clinical s Double-Blind Method Dual energy X-ray absorptiometry Glucose Hormone replacement therapy Humans Insulin Insulin - blood Insulin resistance Insulin Resistance - physiology Male Middle Aged Octreotide Placebos Statistical analysis Testosterone Testosterone - administration & dosage Testosterone - blood Treatment Outcome |
| Title | Long-Term Testosterone Administration on Insulin Sensitivity in Older Men With Low or Low-Normal Testosterone Levels |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201804000-00052 https://www.ncbi.nlm.nih.gov/pubmed/29373734 https://www.proquest.com/docview/2030628364 https://www.proquest.com/docview/3170008232 https://www.proquest.com/docview/1992008228 https://pubmed.ncbi.nlm.nih.gov/PMC6276701 |
| Volume | 103 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF9qCyKI1Kr1tC0rlD6IC5fsV-5J-kmrd1fRK97bkmw2trUktbnSf9-ZzV5s6FUucIQdNsvO7GQmM_MbQraTYpBHGWg_lXLOBGhhlkqVMZmpNO-nLrIpRnRHY3V8Jr5M5TR8cKtDWuVcJ3pFnVcWv5GDk86x3I8r8fn6D8OuURhdDS00npCVCCwRbN2gp63DBb5CQKHENAQdTwPGJlatXCJ8ISwRi8Fl553UqXO7Z24-zJp8fldhRLv-7RPa772WjlbJi2BP0t1GAF6SJVeukaejEDF_RWbDqvzFJqB_6QSbyCAuQlU62gXNpXCdNFnp9AemtDc9JSjcnmIbbzpyJf15MTunw-qOVjf4x8Zo7l51px1iDlL9mpwdHU72j1notMCsjIVk4FHrYiAGqcy5Rp9CahurQoqCO5k7aXmRFDwTyvlCWdgDFTuw5EQeg34cWP6GLJfwlLeEKh1Lrl2_yHQqMi0z15eJzsHtsx6Ipkc-zffa2ABDjt0wrgy6I8Aac2kNssZ41vTITkt-3eBvPEb4ARj3GA0LNBtztppwVGvzT7AWDnMEMMRwZAxPaIfhDGJgJS1ddVsbTOH10PlJj6w3QtIuBMwpDT-YXHfEpyVAfO_uSHlx7nG-VayV7kc9wjqCZpoKWePdO7A1QNFFCepiDxEgYZ0fF9Iv3JJ3_9-S9-QZzt6kKm2Q5dnNrdsEK2yWbfmjtkVW9g7H377D3cHJ179lrC9t |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwELdGJwESQrxXGGAk4APCUhu_0g8T4rGpZW1B0Il-M4nj7MGUjKVTxT_H38Zd4oRFdHybUimqfLIj3-V8l7v7HSHPw3SQ9GPQfirinAnQwiySKmYyVlHSi1zfRhjRnUzVcE98nMv5Gvld18JgWmWtE0tFneQWv5GDk86x3I8r8ebkJ8OuURhdrVtoRL61QrJVQoz5wo5d92sJLlyxNfoA_H4RBDvbs_dD5rsMMCsDIRl4kzodiEEkE67RnpbaBiqVIuVOJk5anoYpj4VyZZGoS6wKHFgxIglANwwsh3mvkHWBH1A6ZP3d9vTzlyaOIYTHwcRECB3MPcon1s0cIYAibBKWo8vWqdiqtDtn8P6bt3ljmWNMvfhRptSfOxh3bpGb3qKlbysRvE3WXHaHXJ34mP1dshjn2T6bwQlAZ9jGBpEZ8szRNmwvhd-oyounXzGpvupqQeHvJ2wkTicuo98OFwd0nC9pfoo3NkWD-7g97RizoIp7ZO9SuHCfdDJYZYNQpQPJteulsY5ErGXsejLUCTietoTC6ZLX9V4b64HQsR_HsUGHCFhjjqxB1piSNV3ysiE_qRBALiJ8Boy7iIZ5ms2arcYri8L8Fe2VwxwhFDEgGsAKzTBoAQztRJnLzwqDScQleH_YJQ8qIWkeBAw6DRdMrlvi0xAgwnh7JDs8KJHGVaCV7vW7hLUEzVQ1uqZ0MMHaAVXbD_E0KEEKJDznq5X0K7fk4f-35Cm5NpxNxmY8mu4-ItdxpSpxapN0Fqdn7jHYhIv4iX_xKPl-2e_6H7bJcCg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-Term+Testosterone+Administration+on+Insulin+Sensitivity+in+Older+Men+With+Low+or+Low-Normal+Testosterone+Levels&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Huang%2C+Grace&rft.au=Pencina%2C+Karol+M&rft.au=Li%2C+Zhuoying&rft.au=Basaria%2C+Shehzad&rft.date=2018-04-01&rft.eissn=1945-7197&rft.volume=103&rft.issue=4&rft.spage=1678&rft_id=info:doi/10.1210%2Fjc.2017-02545&rft_id=info%3Apmid%2F29373734&rft.externalDocID=29373734 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |